1. Inicio
  2. Publicaciones
  3. Enhanced Metabolic Syndrome Management Through Cannabidiol-Loaded PLGA Nanoparticles: Development and In Vitro Evaluation.

Enhanced Metabolic Syndrome Management Through Cannabidiol-Loaded PLGA Nanoparticles: Development and In Vitro Evaluation.

Fecha de publicación:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • El-Hammadi MM
  • Martín-Navarro L
  • Berrocoso E
  • Álvarez-Fuentes J
  • Crespo-Facorro B
  • Suárez-Pereira I
  • Martín-Banderas L

Unidades

Abstract

Cannabidiol (CBD) holds promise for managing metabolic diseases, yet enhancing its oral bioavailability and efficacy remains challenging. To address this, we developed polymeric nanoparticles (NPs), using poly(lactic-co-glycolic acid) (PLGA), encapsulating CBD using nanoprecipitation, aiming to create an effective CBD-nanoformulation for metabolic disorder treatment. These NPs (135-265 nm) demonstrated high encapsulation efficiency (EE% ˜ 100%) and sustained release kinetics. Their therapeutic potential was evaluated in an in vitro metabolic syndrome model employing sodium palmitate-induced HepG2 cells. Key assessment parameters included cell viability (MTT assay), glucose uptake, lipid accumulation (Oil Red O staining), triglycerides, cholesterol, HDL-c levels, and gene expression of metabolic regulators. Results showed an IC50 of 9.85 µg/mL for free CBD and 11.26 µg/mL for CBD-loaded NPs. CBD-loaded NPs significantly enhanced glucose uptake, reduced lipid content, lowered triglycerides and total cholesterol, and increased HDL-c levels compared to free CBD. Gene analysis indicated reduced gluconeogenesis via downregulation of PPAR?, FOXO-1, PEPCK, and G6Pase and enhanced fatty acid oxidation through CPT-1 upregulation. These findings suggest that CBD-loaded NPs may serve as a novel therapeutic strategy for the management of metabolic disorders, warranting further in vivo studies.

© 2025 Wiley Periodicals LLC.

Datos de la publicación

ISSN/ISSNe:
1549-3296, 1552-4965

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A  John Wiley & Sons Inc.

Tipo:
Article
Páginas:
37916-37916
PubMed:
40277882

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • antipsychotics; cannabidiol; diabetes; lipid metabolism; metabolic disorders; nanomedicine

Campos de Estudio

Financiación

FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA (INNVAL18/30)
INSTITUTO DE SALUD CARLOS III. (INT22/00029)
Ministerio de Ciencia e Innovacion (PRE2022-101521)
Plan Estatal 2021-2023, Ministerio de Ciencia e Innovacion (PID2021-122714OB-I00)
Plan Nacional sobre Drogas (Ministerio de Sanidad, Gobierno de Espana) (2021I079)

Proyectos asociados

Novel pharmacologic formulation of cannabidiol (CBDloaded nanoparticles) and effect on antipsychotic-induced weight gain and related metabolic alterations

Investigador Principal: Javier Vázquez Bourgon

INNVAL18/30 . FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA . 2018

Ayudas Intensificación VAZQUEZ BOURGON JAVIER

Investigador Principal: Javier Vázquez Bourgon

INT/A20/04 . 2021

Ayudas Intensificación VÁZQUEZ BOURGON JAVIER

Investigador Principal: Javier Vázquez Bourgon

INT/A21/10 . 2021

Contrato para la intensificación de la actividad investigadora en el SNS

Investigador Principal: Javier Vázquez Bourgon

INT22/00029 . 2023

Compartir